Serratia
Report Name: 2003 Pediatric Serratia marcescens
Query Selection Criteria:
Report Start Date: 01/01/2003 (MM/DD/YYYY)
Report End Date: 12/31/2003 (MM/DD/YYYY)
Organism: Serratia marcescens
Drug: Amikacin;Ampicillin;Cefazolin;Cefepime;Cefotaxime;Ceftazidime;Ce
ftriaxone;Ciprofloxacin;Colistin;Gentamicin;Imipenem;Nitrofurantoi
n;Piperacillin;Piperacillin/tazobactam;Tobramycin;Trimeth/sulfa
Breakpoint: NCCLS
Patient Type: Inpatient;Inpatient - ICU;Outpatient
Patient Age: greater than or equal to 0 AND less than or equal to 18
Institution: T84 University of CA at San Francisco - Parnassus
Street-ALL;T84 Mt. Zion Medical Center - Divisedero Street
Trending: None
Dataset: Institution
Chosen Country: United States
Organism Serratia marcescens S S I I R R
Drug Total N % N % N %
Amikacin 20 20 100.0 % 0 0.0 % 0 0.0 %
Ampicillin 20 0 0.0 % 1 5.0 % 19 95.0 %
Cefazolin 20 0 0.0 % 0 0.0 % 20 100.0 %
Cefepime 20 20 100.0 % 0 0.0 % 0 0.0 %
Cefotaxime 20 17 85.0 % 2 10.0 % 1 5.0 %
Ceftazidime 20 18 90.0 % 1 5.0 % 1 5.0 %
Ceftriaxone 20 20 100.0 % 0 0.0 % 0 0.0 %
Ciprofloxacin 20 20 100.0 % 0 0.0 % 0 0.0 %
Gentamicin 20 17 85.0 % 2 10.0 % 1 5.0 %
Imipenem 20 20 100.0 % 0 0.0 % 0 0.0 %
Nitrofurantoin 6 0 0.0 % 0 0.0 % 6 100.0 %
Piperacillin 14 10 71.4 % 4 28.6 % 0 0.0 %
Piperacillin/tazobactam 20 17 85.0 % 2 10.0 % 1 5.0 %
Tobramycin 20 17 85.0 % 2 10.0 % 1 5.0 %
Trimeth/sulfa 20 20 100.0 % 0 0.0 % 0 0.0 %
For agents with >25% of strains tested:
Plain=<60% activity